Pacific Edge (NZE:PEB, ASX:PEB) said the Medicare coverage for its flagship Cxbladder test has been extended by two months to Thursday, April 24, according to a Monday filing with the New Zealand and Australian bourses.
Last Jan. 22, the cancer diagnostics company disclosed plans to seek a preliminary injunction in the US relating to the removal of Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge's shares were up 7% in New Zealand and 10% in Australia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。